Drug and Alcohol Dependence
Volume 111, Issue 1 , Pages 44-49 , 1 September 2010

Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia

  • B. Vicknasingam

      Affiliations

    • Centre for Drug Research, Universiti Sains Malaysia, 11800 Penang, Malaysia
    • Corresponding Author InformationCorresponding author. Tel.: +60 4 6532140; fax: +60 4 6568669.
    • ,
  • M. Mazlan

      Affiliations

    • Substance Abuse Research Centre, Muar, Johor 84000, Malaysia
    • ,
  • R.S. Schottenfeld

      Affiliations

    • Yale University School of Medicine, CMHC/SAC, 34 Park Street, New Haven, CT 06519, USA
    • ,
  • M.C. Chawarski

      Affiliations

    • Yale University School of Medicine, CMHC/SAC, 34 Park Street, New Haven, CT 06519, USA

Received 7 December 2009 ,Revised 16 March 2010 ,Accepted 16 March 2010.

References 

  1. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine–naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88:75–78
  2. Bruce RD, Govindasamy S, Sylla S, Haddad MS, Kamarulzaman A, Altice F. Case series of buprenorphine injectors in Kuala Lumpur, Malaysia. Am. J. Drug Alcohol Abuse. 2008;34:511–517
  3. Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice F. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am. J. Drug Alcohol Abuse. 2009;35:68–72
  4. Cicero TJ, Surratt H, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J. Opioid Manage. 2007;3:1–7
  5. Chawarski MC, Pakes J, Schottenfeld RS. Assessment of HIV risk. J. Addict. Dis. 1998;17:49–59
  6. Chua S-M, Lee T-S. Abuse and prescription buprenorphine, regulatory controls. Ann. Acad. Med. 2006;35:492–495
  7. Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J. Pharmacol. Exp. Ther. 2002;70:S29–S37
  8. Institute of Medicine . Preventing HIV Infection among Injecting Drug Users in High Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press; 2006;
  9. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?. Addiction. 2005;100:197–205
  10. Hakansson A, Medvedeo A, Andersson M, Berglund M. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Eur. Addict. Res. 2007;13:207–215
  11. Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000;61:85–94
  12. Lee CE. Tackling subutex abuse in Singapore. Singapore Med. J. 2006;47:919
  13. Mammen K, Bell J. The clinical efficacy and abuse potential of combination buprenorphine–naloxone in the treatment of opioid dependence. Expert Opin. Pharmacother. 2009;10:2537–2544
  14. Mandelson J, Jones RT. Clinical and pharmacological evaluations of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment. Drug Alcohol Depend. 2003;70:S29–37
  15. Mazlan M, Vicknasingam B, Chawarski MC, Schottenfeld RS. Characteristics of opiate IDUs with and without ATS abuse in Kuala Lumpur, Malaysia. In: College on the Problems of Drug Dependence 71st Annual Scientific Meeting. June 20–25 Reno, Nevada, USA. 2009;
  16. Narcotics Bulletin . Ministry of Internal Security and Home Affairs Malaysia. 2007;
  17. National Anti Drug Agency, National Drug Information System . Ministry of Internal Security and Home Affairs Malaysia. January 2007;
  18. Nielsen S, Dietze P, Lee N, Dunlop A, Taylor D. Concurrent buprenorphine and benzodiazepine use and self-reported opioid toxicity substitution treatment. Addiction. 2007;102:616–622
  19. Nigam AK, Srivastava RP, Saxena S, Chavan BS, Sundaram KR. Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction. 1994;89:317–320
  20. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction. 2001;96:267–272
  21. Robinson GM, Dukes PD, Robinson BJ, Cooke RR, Mahoney GN. The misuse of buprenorphine and buprenorphine–naloxone combination in Wellington, New Zealand. Drug Alcohol Depend. 1993;33:81–86
  22. Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2192–2200
  23. Singh RA, Mattoo SK, Malhotra A, Varma VK. Cases of buprenorphine abuse in India. Acta Psychiat. Scand. 1992;86:46–48
  24. Strang J. Abuse of buprenorphine. Lancet. 1985;28:725
  25. The Star . Tougher Penalties for Errant Clinics. November 2006;
  26. Vicknasingam B, Navaratnam V. The use of rapid assessment methodology to compliment existing national assessment and surveillance data: a study among injecting drug users in, Penang, Malaysia. Int. J. Drug Policy. 2008;90–93
  27. Vicknasingam B, Mazlan M, Chawraski MC, Schottenfeld RS. Malaysia's evolving response to heroin dependence, injection drug use and HIV/AIDS—initial experience with buprenorphine maintenance treatment. In: NIDA International Forum. June 16–21, Quebec City, Canada. 2007;
  28. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 2003;69:175–181
  29. Villiger JW, Taylor KM. Buprenorphine high-affinity binding to dorsal spinal cord. J. Neurochem. 1982;38:1771–1773

PII: S0376-8716(10)00133-X

doi: 10.1016/j.drugalcdep.2010.03.014

Drug and Alcohol Dependence
Volume 111, Issue 1 , Pages 44-49 , 1 September 2010

Article Tools